Merck & Co. is one of the largest pharmaceutical companies established in 1891. It manufactures and markets a broad range of healthcare products for human and animal use. Merck has annual revenue of $27.4 billion and employs over 61,500 people worldwide. Some of Merck's major products include vaccines, prescription drugs, consumer health products, and animal health medicines. One of Merck's prescription drugs is lisinopril, an ACE inhibitor used to treat hypertension, heart failure, and diabetic complications. It has annual global sales of over $1 billion.

1. PROJECT REPORT ON MERCK & CO

3. Established in 1891 as the United States subsidiary of the German company now known as Merck KGaA

4. 1917 as an independent company

6. BASIC INFORMATION Industry Founded Headquaters Chairman President & CEO Pharmaceuticals 1891 as a subsidiary of Merck KGaA Whitehouse Station, New Jersey, United States Richard T. clarck Stanley F. Barshay

7. CONTINUED Revenue Operating Income Net Income Total assets Total equity Employees US$27.4 Billion US$4.83 Billion US$12.9 Billion US$112 Billion US$59.1 Billion 61,500

8. VISION OF MERCK & CO. We make a difference in the lives of people globally through our innovative medicines, vaccines, and consumer health and animal products. We aspire to be the best healthcare company in the world and are dedicated to providing leading innovations and solutions for tomorrow.

9. MISSION OF MERCK & CO To provide innovative, distinctive products and services that save and improve lives and satisfy customer needs, to be recognized as a great place to work, and to provide investors with a superior rate of return.

10. WHAT WE STAND FOR ???? Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical needs. Focus on patients and anticipating customers needs

11. CONTINUED Commitment to expand access to our medicines and vaccines, and to improve global health

12. PRODUCTS WE DEAL IN …. VACCINES PRESCRIPTION PRODUCTS CONSUMER PRODUCTS ANIMAL HEALTH PRESCRIBING INFORMATION

13. RESPONSIBILITY OF MERCK & CO. ETHICS & TRANSPARENCY ACCESS ENVIRONMENT COMMUNITY

14. OBJECTIVE OF MERCK & CO To develop policy positions that guide our activities and advocacy on a range of issues To seek opportunities to adopt industry-leading standards in several areas To strive to communicate clearly and transparently about our positions

15. CONTINUED To work closely with the many groups and individuals who are also trying to address the complex healthcare challenges that confront us

16. PRODUCTS ON THE MARKET Antivenin - for the treatment of Black Widow Spider bites Arcoxia (etoricoxib) - for the symptomatic treatment of osteoarthritis Cancidas (caspofungin) - An echinocandins antifungal drug for treatment of Aspergillus and Candida

17. CONTINUED Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertension. Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.

18. CONTINUED Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy. Crixivan (indinavir) – a protease inhibitor HIV medication. Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.

19. CONTINUED Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy Emend Injection (fosaprepitantdimeglumine) - an intravenous drug for nausea and vomiting caused by chemotherapy Emflex (Acemetacin) - a non-steroidal anti-inflammatory drug

20. CONTINUED Fosamax (alendronate) – osteoporosis medication. Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication Isentress (raltegravir) - HIV integrase inhibitor.

21. COMMON ST. OF MERCK & CO

22. REVENUE GRAPH OF MERCK & CO.

23. COMPETITORS IN UK NAMEOF THE COMPANY TOTAL REVENUE (IN USD BILLIONS) 45.83 32.81 GlaxoSmithKline AstraZeneca

25. COMPETITORS IN SWITZERLAND NAME OF THE COUNTRY HOFFMAN LA ROCHE NOVARTIS NYCOMED TOTAL REVENUE (IN USD BILLIONS) 47.35 44.27 4.26

26. COMPETITORS IN GERMANY NAME OF THE COUNTRY BAYER BOEHRINGER INGELHEIM MERCK kGaA TOTAL REVENUE (IN USD BILLIONS) 22.3 16.9 5.17

27. COMPETITORS IN JAPAN NAME OF THE COUNTRY TAKEDAPHARMACEUTICAL ASTELLAS PHARMA DAIICHI SANKYO 9 EISAI CHUGAI PHARMACEUTICAL . TOTAL REVENUE (IN USD BILLIONS) 15.6 10.7 9 5.5 2.0

28. SELECTIVE PRODUCT :LISINOPRIL It is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared withomapatrilat which is of similar function.

31. SYSTEMATIC IMAGE

32. IDENTIFIERS CAS number ATC code PubChemode 8C09AA03 3915-83-7 CID 5362119

33. CHEMICAL DATA Formula Mol. Mass SMILES InChISynonyms C21H31N3O5 405.488 g/mol Emolecules & Pubchem (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid

34. Pharmacology Lisinopril is the lysine-analog of enalapril Lisinopril is not a pro drug and is excreted unchanged in the urine In cases of overdosage, it can be removed from circulation by dialysis

35. CLINICAL USE Its indications, contraindications and side effects are as those for all ACE inhibitors Its long half-life allows for once a day dosing which aids patient compliance Patients whose creatinine clearance ≥10 mL/min and ≤30 mL/min should be given the standard 5 mg/day dosage, at first

36. CONTINUED For patients whose creatinine clearance is less than 10 mL/min, the dosage should start at 2.5 mg/day, adjusted over time according to the patient's blood pressure response

37. ADVERSE EFFECTS Chills, infection Dark urine, decreased urination Difficulty swallowing or breathing Hoarseness Itching

38. CONTINUED Rapid weight gain, stomach pain Yellowing of skin or eyes (jaundice) Abdominal pain, bloating, vomiting Chest pain or tightness, dizziness, lightheadedness, fainting (syncope)

39. CONTINUED Dry cough Fever Joint pain Rash Diarrhea, loss of taste, nausea

40. REVENUE OF LISINOPRIL

41. MARKET SHARE OF LISINOPRIL

42. Thank You Presented By :- REEMA PUNIANI (M100700046)